A photo of Ashish Kumar.

Ashish R. Kumar, MD, PhD


  • Director, Histiocytosis Center
  • Director, Hematology/Oncology Fellowship Program
  • Professor, UC Department of Pediatrics
I try to individualize my delivery of information and care to each patient and their family, while maintaining a high quality of care and treatment.

About

Biography

I've always been fascinated by nature and science. Diseases of the blood and immune system have been called "experiments of nature," which have led to a better understanding of natural biology itself.

As a pediatric hematologist/oncologist, I specialize in histiocyte disorders, primary immune deficiency diseases and bone marrow transplantation. Working with children who have these disorders has provided me valuable lessons about life and medicine. In my practice, I try to individualize my delivery of information and care to each patient and their family, while maintaining a high quality of care and treatment.

Based on research and experience, we have completely changed our approach to treatment for diseases like Langerhans cell histiocytosis (LCH), where we don't use chemotherapy at all. Instead, novel oral inhibitors have revolutionized the outcomes for patients with this condition. We also have a different way of diagnosing patients with hemophagocytic lymphohistiocytosis (HLH), which has resulted in improved outcomes.

In my research, my colleagues and I are looking at two childhood diseases: LCH and infant leukemia. With newer therapies, we have improved outcomes of patients with LCH. However, we still don't have a cure, which would relieve patients of the need to take medications. Infant leukemia remains a largely incurable disease. We are studying the biology of LCH and infant leukemia in the laboratory to develop novel therapies.

One of my most significant honors was participating in the 700 Miles to Hope bike ride, where I rode my bicycle 700 miles over seven days with families of patients affected by HLH. The goal was to raise awareness and funds for HLH research and care, but it ended up doing much more. I learned and discovered so much about people and myself and made many long-lasting friendships.

In my free time, I enjoy traveling, hiking and cooking. I love music, although the only instrument I can play is the air guitar.

Additional Languages

Hindi

Location

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients. Hashem, H; Bucciol, G; Ozen, S; Unal, S; Bozkaya, IO; Akarsu, N; Taskinen, M; Koskenvuo, M; Saarela, J; Dimitrova, D; et al. Journal of Clinical Immunology. 2021; 41:1633-1647.

Reduced-Intensity/Reduced-Toxicity Conditioning Approaches Are Tolerated in XIAP Deficiency but Patients Fare Poorly with Acute GVHD. Arnold, DE; Nofal, R; Wakefield, C; Lehmberg, K; Wustrau, K; Albert, MH; Morris, EC; Heimall, JR; Bunin, NJ; Kumar, A; et al. Journal of Clinical Immunology. 2021.

Daratumumab for the management of autoimmune cytopenias in children and young adults: a case series. Khandelwal, P; Teusink-Cross, A; Kumar, AR; Bleesing, JJ; Mehta, PA; Jordan, MB; Chandra, S; Davies, SM; Marsh, RA. British Journal of Haematology. 2021; 194:e84-e89.

LAMP-5 is an essential inflammatory-signaling regulator and novel immunotherapy target for Mixed Lineage Leukemia-Rearranged acute leukemia. Gracia-Maldonado, G; Clark, J; Burwinkel, M; Greenslade, B; Wunderlich, M; Salomonis, N; Leone, D; Gatti, E; Pierre, P; Kumar, AR; et al. Haematologica. 2021.

Discrepancies between F-18-FDG PET/CT findings and conventional imaging in Langerhans cell histiocytosis. Ferrell, J; Sharp, S; Kumar, A; Jordan, M; Picarsic, J; Nelson, A. Pediatric Blood and Cancer. 2021; 68.

Ruxolitinib for the treatment of chronic GVHD and overlap syndrome in children and young adults. Wang, YM; Teusink-Cross, A; Elborai, Y; Krupski, MC; Nelson, AS; Grimley, MS; Flannery, A; Mehta, PA; Bleesing, JJ; Chandra, S; et al. Transplantation. 2021.

Experience with a Reduced Toxicity Allogeneic Transplant Regimen for Non-CGD Primary Immune Deficiencies Requiring Myeloablation. Chandra, S; Chandrakasan, S; Dávila Saldaña, BJ; Bleesing, JJ; Jordan, MB; Kumar, AR; Grimley, MS; Krupski, C; Davies, SM; Khandelwal, P; et al. Journal of Clinical Immunology. 2021; 41:89-98.

Developmental Adaptive Immune Defects Associated with STAT5B Deficiency in Three Young Siblings. Foley, CL; Al Remeithi, SS; Towe, CT; Dauber, A; Backeljauw, PF; Tyzinski, L; Kumar, AR; Hwa, V. Journal of Clinical Immunology. 2021; 41:136-146.

Non-Tuberculous Mycobacterial Infection in Hematopoietic Cell Transplant. Sabulski, A; Davies, SM; Paulsen, G; Kumar, A; Grimley, M; Chandra, S. Journal of Clinical Immunology. 2020; 40:1171-1175.

MBNL1 regulates essential alternative RNA splicing patterns in MLL-rearranged leukemia. Itskovich, SS; Gurunathan, A; Clark, J; Burwinkel, M; Wunderlich, M; Berger, MR; Kulkarni, A; Chetal, K; Venkatasubramanian, M; Salomonis, N; et al. Nature Communications. 2020; 11.

From the Blog


A Ride For HLH Research
BlogRare and Complex Conditions

A Ride For HLH Research

By Ashish Kumar, MD, PhD1/17/2019

A Message from Dr. Kumar – Learn about HLH, Become a Donor
BlogRare and Complex Conditions

A Message from Dr. Kumar – Learn about HLH, Become a Donor

By Ashish Kumar, MD, PhD9/23/2016

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey